An Open Study to Evaluate Whether Pack Size Affects Compliance of Metformin Treatment in Subjects With Type II Diabetes
NCT01817777 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 31
Last updated 2017-01-09
Summary
MTF116086 is an open-label, randomised, parallel-design study in subjects with type II diabetes. The study is site-based, with local pharmacies serving as the sites and pharmacists as principal investigators for the sites. All subjects will enter an initial 8-week observational phase during which purchase behaviour and compliance with usual metformin use will be observed and recorded. At the end of the observational phase, subjects will be randomised to one of the two arms (metformin small pack vs. metformin large pack) for a 20-week interventional phase. The medication in the interventional phase is provided to the subjects free of charge. HbA1c will be collected for all subjects during Week 0, Week 8, and Week 28. Subjects will be asked questions about their tablet compliance, their satisfaction with the pack size they received and reasons for missing doses throughout the interventional phase by the pharmacist. The pharmacy visit on Week 28 will be end of the study.
Conditions
- Diabetes Mellitus, Type 2
Interventions
- DRUG
-
Metformin Small Pack
A single small pack of metformin will consist of a blister package containing 10 pills with a patient information leaflet in local language. The small packs will be available at each site in the following doses: 500 mg, 850 mg, and 1000 mg. The small pack size of metformin is not yet marketed. Small pack metformin will be provided by GSK as GSK brand metformin.
- DRUG
-
Metformin Large Pack
The large pack will consist of 1 month's supply of metformin.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-05-31
- Primary Completion
- 2014-02-28
- Completion
- 2014-02-28
Countries
- Argentina
Study Locations
More Related Trials
-
Clinical Trial to Evaluate Safety and pK Profile of Metformin Glycinate in Healthy Volunteers
NCT01560481 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)
NCT00961480 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic and Pharmacodynamic Study of Metformin and Canagliflozin in Healthy Adult Volunteers
NCT01273571 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
NCT01376323 ·Status: COMPLETED ·Phase: PHASE2
-
To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately
NCT01535677 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of the Bioavailability of Metformin Between Medium Dose Linagliptin/Metformin Tablets and Medium Dose Glucophage Tablet Given With Linagliptin Tablet
NCT01383356 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin Tablets
NCT01510522 ·Status: WITHDRAWN ·Phase: PHASE4
-
Fed Bioequivalence Study of 2 Metformin 500 mg Prolongued Release Tablets in 28 Healthy Male and Female Volunteers
NCT05124717 ·Status: COMPLETED ·Phase: PHASE1
-
A Relative Bioavailability Study of Metformin HCL Tablets, 1000 mg Under Fasting Conditions
NCT00865033 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)
NCT01093794 ·Status: COMPLETED ·Phase: PHASE1
-
Fasting Bioequivalence Study of 2 Metformin 500 mg Prolonged Release Tablets in 44 Healthy Male and Female Volunteers
NCT05124730 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fasted, Healthy, Adult Subjects
NCT00944177 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes
NCT00971243 ·Status: COMPLETED ·Phase: PHASE2
-
A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
NCT01128621 ·Status: COMPLETED ·Phase: PHASE2
-
Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets Versus Glucophage XR® 750 mg Tablet in Healthy Volunteers Under Fed Conditions.
NCT01089205 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy Volunteers
NCT01216397 ·Status: COMPLETED ·Phase: PHASE1
-
A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY
NCT04617275 ·Status: COMPLETED ·Phase: PHASE2
-
Bioequivalence Study of Metformin Hydrochloride 1000mg Tablets Under Fasting Conditions
NCT00778427 ·Status: COMPLETED ·Phase: NA
-
Fasting Bioequivalence Study of 2 Metformin 1000 mg Prolonged Release Tablets in 28 Healthy Male and Female Volunteers
NCT05123781 ·Status: COMPLETED ·Phase: PHASE1
-
Comparative Bioavailability Study of Metformin/Sitagliptin 850 mg/50 mg Tablets in Healthy Male and Female Volunteers
NCT05549570 ·Status: COMPLETED ·Phase: PHASE1
-
Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers
NCT01725672 ·Status: TERMINATED ·Phase: PHASE1
-
Efficacy Study of Metformin Glycinate on Postprandial Lipemia
NCT02064881 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)
NCT00899470 ·Status: COMPLETED ·Phase: PHASE1
-
Metformin in Non-Alcoholic Fatty Liver Disease
NCT00303537 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy Participants
NCT05550129 ·Status: COMPLETED ·Phase: PHASE1